Clean Room and GMP Quiz

Correct!

GMP reference: PE 009-13, Part I, Chapter 1 Pharmaceutical Quality System, 1.4, page 3

“(xiv) An appropriate level of root cause analysis should be applied during the investigation of deviations, suspected product defects and other problems.

This can be determined using Quality Risk Management principles. In cases where the true root cause(s) of the issue cannot be determined, consideration should be given to identifying the most likely root cause(s) and to addressing those. Where human error is suspected or identified as the cause, this should be justified having taken care to ensure that process, procedural or system based errors or problems have not been overlooked, if present. Appropriate corrective actions and/or preventive actions (CAPAs) should be identified and taken in response to investigations. The effectiveness of such actions should be monitored and assessed, in line with Quality Risk Management principles.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 1 Pharmaceutical Quality System, 1.6, page 3

“There should be periodic management review, with the involvement of senior management, of the operation of the Pharmaceutical Quality System to identify opportunities for continual improvement of products, processes and the system itself”.

Correct! The GMP reference is GMP reference PE 009-13, Part I, Chapter 1 Product Quality Review, 1.10, page 6
“A review of starting materials including packaging materials used in the product, especially those from new sources and in particular the review of supply chain traceability of active substances”

PE009-13, the PIC/S guide to GMP for medicinal products TGA interpretation and expectations for demonstrating compliance:

“Manufacturers of dosage forms should have a clear understanding of the approved suppliers of active substances, and each entity and their responsibility in the supply chain between the site of manufacture and receipt (clause 1.10(i)). Supply chains should be adequately secure, integral and ensure that materials are transported under appropriate conditions. Supply chains should be mapped and any identified risks managed following the principles of quality risk management.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 2 Personnel, 2.11, page 11

“Besides the basic training on the theory and practice of the Pharmaceutical Quality System and Good Manufacturing Practice, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness should be periodically assessed. Training programmes should be available, approved by either the head of Production or the head of Quality Control, as appropriate. Training records should be kept.”

Correct! The GMP reference is Refer to PE 009-13, Part I, Chapter 7 Outsourced Activities, 7.4, page 40

“The Pharmaceutical Quality System of the Contract Giver should include the control and review of any outsourced activities”

PE009-13, the PIC/S guide to GMP for medicinal products TGA interpretation and expectations for demonstrating compliance

“The title of chapter 7 has changed from ‘Contract manufacturer and analysis’ to ‘Outsourced activities’ in recognition of the fact that there are a number of outsourced (contracted) activities that may have a direct effect on the quality of medicinal product manufactured by a site. The previous title of the chapter restricted the extent of GMP controls to only outsourced manufacturing and testing services and thus did not appropriately manage the risk associated with other outsourced activities. Examples of outsourced activities that this chapter would now apply to include, but are not limited to:

-Contract manufacturing and analysis

-Maintenance and calibration services

-Providers of critical consumables, e.g. gowns, sterilised componentry

-Suppliers and manufacturers of raw materials, packaging materials and printed artwork

-Provision of training and consulting services

-Validation services associated with facilities, equipment, utilities, process and product design, qualification and validation

-Provision of transport and logistical services for products

-Contract cleaning and waste management services

-Contract pest control services

-Agencies that provide temporary or contract personnel”

Correct! The GMP reference is PE 009-13, Part I, Chapter 2 Personnel, 2.23, page 12

“Consultants should have adequate education, training, and experience, or any combination thereof, to advise on the subject for which they are retained. Records should be maintained stating the name, address, qualifications, and type of service provided by these consultants”.

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.41, page 16

“Measuring, weighing, recording and control equipment should be calibrated and checked at defined intervals by appropriate methods. Adequate records of such tests should be maintained.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.1, page 18

“All types of document should be defined and adhered to. The requirements apply equally to all forms of document media types. Complex systems need to be understood, well documented, validated, and adequate controls should be in place. Many documents (instructions and/or records) may exist in hybrid forms, i.e. some elements as electronic and others as paper based. Relationships and control measures for master documents, official copies, data handling and records need to be stated for both hybrid and homogenous systems. Appropriate controls for electronic documents such as templates, forms, and master documents should be implemented. Appropriate controls should be in place to ensure the integrity of the record throughout the retention period.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.8, page 19

“Records should be made or completed at the time each action is taken and in such a way that all significant activities concerning the manufacture of medicinal products are traceable.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.29, page 25

“There should be written policies, procedures, protocols, reports and the associated records of actions taken or conclusions reached, where appropriate, for the following examples:

– Validation and qualification of processes, equipment and systems;
– Equipment assembly and calibration;
– Technology transfer;
– Maintenance, cleaning and sanitation;
– Personnel matters including signature lists, training in GMP and technical matters, clothing and hygiene and verification of the effectiveness of training;
– Environmental monitoring;
– Pest control;
– Complaints;
– Recalls;
– Returns;
– Change control;
– Investigations into deviations and non-conformances;
– Internal quality/GMP compliance audits;
– Summaries of records where appropriate (e.g. product quality review);
– Supplier audits.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 6 Quality control, 6.19, page 36

“Special attention should be given to the quality of laboratory reagents, solutions, glassware, reference standards and culture media. They should be prepared and controlled in accordance with written procedures. The level of controls should be commensurate to their use and to the available stability data.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 7 Outsourced activities, 7.1, page 40

“There should be a written contract covering the outsourced activities, the products or operations to which they are related, and any technical arrangements made in connection with it.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 9 Self inspection, 9.1, page 45

“Personnel matters, premises, equipment, documentation, production, quality control, distribution of the medicinal products, arrangements for dealing with complaints and recalls, and self inspection, should be examined at intervals following a pre-arranged programme in order to verify their conformity with the principles of Quality Assurance.”

Correct! PE 009-13, Part I, Chapter 1 Pharmaceutical Quality System, 1.4, page 3

““(xiv) An appropriate level of root cause analysis should be applied during the investigation of deviations, suspected product defects and other problems. This can be determined using Quality Risk Management principles. In cases where the true root cause(s) of the issue cannot be determined, consideration should be given to identifying the most likely root cause(s) and to addressing those. Where human error is suspected or identified as the cause, this should be justified having taken care to ensure that process, procedural or system based errors or problems have not been overlooked, if present. Appropriate corrective actions and/or preventive actions (CAPAs) should be identified and taken in response to investigations. The effectiveness of such actions should be monitored and assessed, in line with Quality Risk Management principles;”

Correct! The GMP reference is PE 009-13, Part I, Chapter 1 Pharmaceutical Quality System, 1.8, page 5

“(xi) Complaints about products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 2 Personnel, 2.9, page 10-11

“The heads of Production, Quality Control and where relevant, Head of Quality Assurance or Head of Quality Unit, generally have some shared, or jointly exercised, responsibilities relating to quality including in particular the design, effective implementation, monitoring and maintenance of the Pharmaceutical Quality System. These may include, subject to any national regulations:

(i) The authorisation of written procedures and other documents, including amendments;
(ii) The monitoring and control of the manufacturing environment;
(iii) Plant hygiene;
(iv) Process validation;
(v) Training;
(vi) The approval and monitoring of suppliers of materials;
(vii) The approval and monitoring of contract manufacturers and providers of other GMP related outsourced activities;
(viii) The designation and monitoring of storage conditions for materials and products;
(ix) The retention of records;
(x) The monitoring of compliance with the requirements of Good Manufacturing Practice;
(xi) The inspection, investigation, and taking of samples, in order to monitor factors which may affect product quality;
(xii) Participation in management reviews of process performance, product quality and of the Pharmaceutical Quality System and advocating continual improvement;
(xiii) Ensuring that a timely and effective communication and escalation process exists to raise quality issues to the appropriate levels of management.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 2 Personnel, 2.11, page 11

“Besides the basic training on the theory and practice of the Pharmaceutical Quality System and Good Manufacturing Practice, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness should be periodically assessed. Training programmes should be available, approved by either the head of Production or the head of Quality Control, as appropriate. Training records should be kept.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.19, page 15

“Storage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, checked and monitored.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.34, page 16

“Manufacturing equipment should be designed, located and maintained to suit its intended purpose.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.41, page 16

“Measuring, weighing, recording and control equipment should be calibrated and checked at defined intervals by appropriate methods. Adequate records of such tests should be maintained.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.1, page 18

“All types of document should be defined and adhered to. The requirements apply equally to all forms of document media types. Complex systems need to be understood, well documented, validated, and adequate controls should be in place. Many documents (instructions and/or records) may exist in hybrid forms, i.e. some elements as electronic and others as paper based. Relationships and control measures for master documents, official copies, data handling and records need to be stated for both hybrid and homogenous systems. Appropriate controls for electronic documents such as templates, forms, and master documents should be implemented. Appropriate controls should be in place to ensure the integrity of the record throughout the retention period.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.8, page 19

“Records should be made or completed at the time each action is taken and in such a way that all significant activities concerning the manufacture of medicinal products are traceable.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 5 Production- General, 5.10, page 25

“There should be written policies, procedures, protocols, reports and the associated records of actions taken or conclusions reached, where appropriate, for the following examples:

– Validation and qualification of processes, equipment and systems;
– Equipment assembly and calibration;
– Technology transfer;
– Maintenance, cleaning and sanitation;
– Personnel matters including signature lists, training in GMP and technical matters, clothing and hygiene and verification of the effectiveness of training;
– Environmental monitoring;
– Pest control;
– Complaints;
– Recalls;
– Returns;
– Change control;
– Investigations into deviations and non-conformances;
– Internal quality/GMP compliance audits;
– Summaries of records where appropriate (e.g. product quality review);
– Supplier audits.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 5 Production, 5.19, page 27-8

“Cross-contamination should be avoided by appropriate technical or organisational measures, for example:

1. a) Production in segregated areas (required for products such as penicillins, live vaccines, live bacterial preparations and some other biologicals), or by campaign (separation in time) followed by appropriate cleaning;
2. b) Providing appropriate air-locks and air extraction;
3. c) Minimising the risk of contamination caused by recirculation or re-entry of untreated or insufficiently treated air;
4. d) Keeping protective clothing inside areas where products with special risk of cross-contamination are processed;
5. e) Using cleaning and decontamination procedures of known effectiveness, as ineffective cleaning of equipment is a common source of cross-contamination;
6. f) Using “closed systems” of production;

g) Testing for residues and use of cleaning status labels on equipment.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 6 Quality control, 6.19, page 36

“Special attention should be given to the quality of laboratory reagents, solutions, glassware, reference standards and culture media. They should be prepared and controlled in accordance with written procedures. The level of controls should be commensurate to their use and to the available stability data.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 7 Outsourced activities, 7.1, page 40

“There should be a written contract covering the outsourced activities, the products or operations to which they are related, and any technical arrangements made in connection with it.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 9 Self inspection, 9.1, page 45

“Personnel matters, premises, equipment, documentation, production, quality control, distribution of the medicinal products, arrangements for dealing with complaints and recalls, and self inspection, should be examined at intervals following a pre-arranged programme in order to verify their conformity with the principles of Quality Assurance.”

Correct! PE 009-13, Part I, Chapter 1 Pharmaceutical Quality System, 1.4, page 3

““(xiv) An appropriate level of root cause analysis should be applied during the investigation of deviations, suspected product defects and other problems. This can be determined using Quality Risk Management principles. In cases where the true root cause(s) of the issue cannot be determined, consideration should be given to identifying the most likely root cause(s) and to addressing those. Where human error is suspected or identified as the cause, this should be justified having taken care to ensure that process, procedural or system based errors or problems have not been overlooked, if present. Appropriate corrective actions and/or preventive actions (CAPAs) should be identified and taken in response to investigations. The effectiveness of such actions should be monitored and assessed, in line with Quality Risk Management principles;”

Correct! The GMP reference is PE 009-13, Part I, Chapter 1 Pharmaceutical Quality System, 1.8, page 5

“(xi) Complaints about products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 2 Personnel, 2.9, page 10-11

“The heads of Production, Quality Control and where relevant, Head of Quality Assurance or Head of Quality Unit, generally have some shared, or jointly exercised, responsibilities relating to quality including in particular the design, effective implementation, monitoring and maintenance of the Pharmaceutical Quality System. These may include, subject to any national regulations:

(i) The authorisation of written procedures and other documents, including amendments;
(ii) The monitoring and control of the manufacturing environment;
(iii) Plant hygiene;
(iv) Process validation;
(v) Training;
(vi) The approval and monitoring of suppliers of materials;
(vii) The approval and monitoring of contract manufacturers and providers of other GMP related outsourced activities;
(viii) The designation and monitoring of storage conditions for materials and products;
(ix) The retention of records;
(x) The monitoring of compliance with the requirements of Good Manufacturing Practice;
(xi) The inspection, investigation, and taking of samples, in order to monitor factors which may affect product quality;
(xii) Participation in management reviews of process performance, product quality and of the Pharmaceutical Quality System and advocating continual improvement;
(xiii) Ensuring that a timely and effective communication and escalation process exists to raise quality issues to the appropriate levels of management.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 2 Personnel, 2.11, page 11

“Besides the basic training on the theory and practice of the Pharmaceutical Quality System and Good Manufacturing Practice, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness should be periodically assessed. Training programmes should be available, approved by either the head of Production or the head of Quality Control, as appropriate. Training records should be kept.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.19, page 15

“Storage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, checked and monitored.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.34, page 16

“Manufacturing equipment should be designed, located and maintained to suit its intended purpose.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 3 Premise and equipment, 3.41, page 16

“Measuring, weighing, recording and control equipment should be calibrated and checked at defined intervals by appropriate methods. Adequate records of such tests should be maintained.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.1, page 18

“All types of document should be defined and adhered to. The requirements apply equally to all forms of document media types. Complex systems need to be understood, well documented, validated, and adequate controls should be in place. Many documents (instructions and/or records) may exist in hybrid forms, i.e. some elements as electronic and others as paper based. Relationships and control measures for master documents, official copies, data handling and records need to be stated for both hybrid and homogenous systems. Appropriate controls for electronic documents such as templates, forms, and master documents should be implemented. Appropriate controls should be in place to ensure the integrity of the record throughout the retention period.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 4 Documentation, 4.8, page 19

“Records should be made or completed at the time each action is taken and in such a way that all significant activities concerning the manufacture of medicinal products are traceable.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 5 Production- General, 5.10, page 25

“There should be written policies, procedures, protocols, reports and the associated records of actions taken or conclusions reached, where appropriate, for the following examples:

– Validation and qualification of processes, equipment and systems;
– Equipment assembly and calibration;
– Technology transfer;
– Maintenance, cleaning and sanitation;
– Personnel matters including signature lists, training in GMP and technical matters, clothing and hygiene and verification of the effectiveness of training;
– Environmental monitoring;
– Pest control;
– Complaints;
– Recalls;
– Returns;
– Change control;
– Investigations into deviations and non-conformances;
– Internal quality/GMP compliance audits;
– Summaries of records where appropriate (e.g. product quality review);
– Supplier audits.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 5 Production, 5.19, page 27-8

“Cross-contamination should be avoided by appropriate technical or organisational measures, for example:

1. a) Production in segregated areas (required for products such as penicillins, live vaccines, live bacterial preparations and some other biologicals), or by campaign (separation in time) followed by appropriate cleaning;
2. b) Providing appropriate air-locks and air extraction;
3. c) Minimising the risk of contamination caused by recirculation or re-entry of untreated or insufficiently treated air;
4. d) Keeping protective clothing inside areas where products with special risk of cross-contamination are processed;
5. e) Using cleaning and decontamination procedures of known effectiveness, as ineffective cleaning of equipment is a common source of cross-contamination;
6. f) Using “closed systems” of production;

g) Testing for residues and use of cleaning status labels on equipment.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 6 Quality control, 6.19, page 36

“Special attention should be given to the quality of laboratory reagents, solutions, glassware, reference standards and culture media. They should be prepared and controlled in accordance with written procedures. The level of controls should be commensurate to their use and to the available stability data.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 7 Outsourced activities, 7.1, page 40

“There should be a written contract covering the outsourced activities, the products or operations to which they are related, and any technical arrangements made in connection with it.”

Correct! The GMP reference is PE 009-13, Part I, Chapter 9 Self inspection, 9.1, page 45

“Personnel matters, premises, equipment, documentation, production, quality control, distribution of the medicinal products, arrangements for dealing with complaints and recalls, and self inspection, should be examined at intervals following a pre-arranged programme in order to verify their conformity with the principles of Quality Assurance.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 9 Self Inspection, Principle section, page 43.

“Self inspections should be conducted in order to monitor the implementation and compliance with Good Manufacturing Practice principles and to propose necessary corrective measures.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 2 Personnel- Key Personnel, 2.3, page 7.

“Key Personnel includes the head of Production, the head of Quality Control, and if at least one of these persons is not responsible for the release of products the authorised person(s) designated for the purpose. Normally key posts should be occupied by full-time personnel. The heads of Production and Quality Control must be independent from each other.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 1 Quality Management- Quality Risk Management, 1.6, page 5.

Correct! The GMP reference is PE 009-12, Part I, Chapter 2, Personnel- Training, 2.11, page 9

“Visitors or untrained personnel should, preferably, not be taken into the production and Quality Control areas. If this is unavoidable, they should be given information in advance, particularly about personal hygiene and the prescribed protective clothing. They should be closely supervised.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 2 Personnel- Personnel Hygiene, 2.16, page 10

“Every person entering the manufacturing areas should wear protective garments appropriate to the operations to be carried out.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 3 Premises and Equipment- General, 3.5, page 11

“Steps should be taken in order to prevent the entry of unauthorised people. Production, storage and quality control areas should not be used as a right of way by personnel who do not work in them.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 4 Documentation- Good Documentation Practices, 4.9, page 17

“Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 4 Documentation- Specifications, 4.13, page 18

“There should be appropriately authorised and dated specifications for starting and packaging materials, and finished products.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 4 Documentation – Procedures and Records, 4.28, page 23

“Records should be maintained for the distribution of each batch of a product in order to facilitate recall of any batch, if necessary.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 5 Production- General, 5.10, page 25

“At every stage of processing, products and materials should be protected from microbial and other contamination.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 5 Production- Prevention of Cross-Contamination in Production, 5.20, page 27

“Measures to prevent cross-contamination and their effectiveness should be checked periodically according to set procedures.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 5 Production- Starting Materials, 5.29, page 28

“Labels should bear at least the following information:
       the designated name of the product and the internal code reference where applicable;
       a batch number given at receipt;
       where appropriate, the status of the contents (e.g. in quarantine, on test, released, rejected);
       where appropriate, an expiry date or a date beyond which retesting is necessary.
When fully computerised storage systems are used, all the above information should not necessarily be in a legible form on the label.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 6 Quality Control- On-going stability programme, 6.32, page 37

“Out of specification or significant atypical trends should be investigated. Any confirmed out of specification result, or significant negative trend, should be reported to the relevant competent authorities. The possible impact on batches on the market should be considered in accordance with chapter 8 of the GMP Guide and in consultation with the relevant competent authorities.”

Correct! The GMP reference is PE 009-12, Part I, Chapter 3 Premises and equipment- Storage Areas, 3.18-3.20, page 13

“3.18 – Storage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products: starting and packaging materials, intermediate, bulk and finished products, products in quarantine, released, rejected, returned or recalled.
3.19 – Storage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, checked and monitored.
3.20 – Receiving and dispatch bays should protect materials and products from the weather. Receptions areas should be designed and equipped to allow containers of incoming materials to be cleaned where necessary before storage.”